Polyrizon (NASDAQ:PLRZ – Get Free Report) announced its quarterly earnings results on Wednesday. The company reported $2.81 earnings per share for the quarter, FiscalAI reports.
Polyrizon Price Performance
Shares of PLRZ opened at $13.75 on Friday. The company’s 50-day moving average is $13.90 and its 200-day moving average is $9.79. Polyrizon has a fifty-two week low of $2.88 and a fifty-two week high of $2,235.00.
Analysts Set New Price Targets
Separately, Weiss Ratings reiterated a “sell (e+)” rating on shares of Polyrizon in a research note on Thursday, January 22nd. One analyst has rated the stock with a Sell rating, According to MarketBeat, the company presently has a consensus rating of “Sell”.
Institutional Inflows and Outflows
A hedge fund recently bought a new stake in Polyrizon stock. Jane Street Group LLC acquired a new position in shares of Polyrizon Ltd. (NASDAQ:PLRZ – Free Report) in the 4th quarter, according to its most recent 13F filing with the Securities and Exchange Commission (SEC). The firm acquired 14,032 shares of the company’s stock, valued at approximately $119,000. Jane Street Group LLC owned about 1.35% of Polyrizon as of its most recent SEC filing.
About Polyrizon
Polyrizon Ltd. is a development stage biotech company specializing in the development of medical device hydrogels delivered in the form of nasal sprays. Polyrizon Ltd. is based in Raanana, Israel.
Recommended Stories
Receive News & Ratings for Polyrizon Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Polyrizon and related companies with MarketBeat.com's FREE daily email newsletter.
